LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | LDN-193189 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4142 | 4033 | 1.0269 | 1.0334 |
| SK-BR-3 | PD184352 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 5866 | 5752 | 1.0198 | 1.0336 |
| BT-20 | PLX-4720 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4142 | 4033 | 1.0270 | 1.0337 |
| BT-20 | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4137 | 4033 | 1.0267 | 1.0338 |
| MCF7 | Enzastaurin | 0.37 | uM | LJP5 | 72 | hr | 1389 | 6125 | 5905 | 1.0364 | 1.0338 |
| Hs 578T | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 765 | 3257 | 3148 | 1.0348 | 1.0338 |
| BT-20 | YM 201636 | 0.12 | uM | LJP5 | 72 | hr | 1334 | 4143 | 4033 | 1.0274 | 1.0343 |
| SK-BR-3 | Seliciclib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5868 | 5752 | 1.0202 | 1.0343 |
| MDA-MB-231 | PD173074 | 0.12 | uM | LJP6 | 72 | hr | 1311 | 5103 | 4935 | 1.0337 | 1.0344 |
| SK-BR-3 | R406 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 5508 | 5418 | 1.0177 | 1.0347 |
| BT-20 | OSI-027 | 0.04 | uM | LJP6 | 72 | hr | 1334 | 4032 | 3925 | 1.0276 | 1.0348 |
| MDA-MB-231 | Pelitinib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 5253 | 5079 | 1.0345 | 1.0350 |
| Hs 578T | Celastrol | 0.12 | uM | LJP6 | 72 | hr | 765 | 3214 | 3101 | 1.0362 | 1.0352 |
| BT-20 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4150 | 4033 | 1.0287 | 1.0355 |
| MDA-MB-231 | Canertinib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 5102 | 4935 | 1.0342 | 1.0355 |
| BT-20 | GSK1059615 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4146 | 4033 | 1.0285 | 1.0361 |
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5875 | 5752 | 1.0214 | 1.0363 |
| MCF 10A | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 1694 | 11663 | 11103 | 1.0504 | 1.0365 |
| MCF 10A | WH-4-025 | 0.04 | uM | LJP5 | 72 | hr | 1694 | 11668 | 11103 | 1.0509 | 1.0368 |
| MCF 10A | Linifanib | 0.12 | uM | LJP6 | 72 | hr | 1694 | 11792 | 11217 | 1.0512 | 1.0369 |
| MDA-MB-231 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 5265 | 5079 | 1.0367 | 1.0371 |
| BT-20 | Nintedanib | 0.12 | uM | LJP6 | 72 | hr | 1334 | 4041 | 3925 | 1.0295 | 1.0373 |
| MCF7 | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 1389 | 6139 | 5905 | 1.0394 | 1.0373 |
| MCF7 | PIK-93 | 0.37 | uM | LJP5 | 72 | hr | 1389 | 6152 | 5905 | 1.0408 | 1.0376 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5881 | 5752 | 1.0225 | 1.0381 |